ENDRA Life Sciences (NDRA) Operating Leases (2019 - 2026)

ENDRA Life Sciences has disclosed Operating Leases across 8 years of filings, most recently posting $327253.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 29.04% year-over-year to $327253.0; the TTM figure through Mar 2026 stood at $327253.0 (down 29.04% YoY), while the FY2025 annual figure was $362974.0, down 37.89% from the prior year.
• Operating Leases retreated to $327253.0 in Q1 2026, from $362974.0 in the prior quarter.
• Over the last five years, Operating Leases for NDRA reached as high as $618735.0 in Q1 2022 and fell as low as $49823.0 in Q3 2024.
• The 5-year median for Operating Leases is $444167.0 (2023), against an average of $398166.8.
• Annual changes were most pronounced in 2024 — Operating Leases tumbled 78.99% — and 2025, when it surged 954.39%.
• A 5-year view of Operating Leases shows it stood at $518147.0 in 2022, then tumbled by 62.93% to $192062.0 in 2023, then surged by 204.29% to $584419.0 in 2024, then slumped by 37.89% to $362974.0 in 2025, then slipped by 9.84% to $327253.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $327253.0, $362974.0, and $525328.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.